News
Lilly takes POINT in radiopharma push Eli Lilly has made a foray into the radiopharmaceuticals category with an agreement to buy POINT Biopharma for around $1.4 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback